Phase 2
Completed N=90
Comparison of Efficacy of Vitamin D and Vitamin D-calcium Fortified Yogurt Drink in Diabetic Patients
Source: ClinicalTrials.gov NCT01229891 ↗Enrolled (actual)
90
Serious AEs
0.0%
Results posted
Jan 2012
Primary outcomePrimary: Serum 25-hydroxyvitamin D — 45.6; 76.2; 78.4 nmol/L
Summary
The aim of this study is to evaluate the possible effects of daily intake of yogurt drink fortified with vitamin D alone or with vitamin D + calcium on some selected glycemic, metabolic, inflammatory and oxidative stress markers in patients with type 2 diabetes (T2DM).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Serum 25-hydroxyvitamin D |
45.6; 76.2; 78.4 | — |
| SECONDARY Fasting Serum Glucose (FSG) |
203.3; 171.2; 174.3 | — |
| SECONDARY Insulin |
10.8; 6.5; 6.4 | — |
| SECONDARY Hemoglobin A1c (HbA1c) |
8.7; 7; 7.8 | — |
| SECONDARY Serum Triglyceride (TG) |
181.3; 155.2; 161.1 | — |
| SECONDARY Serum Total Cholesterol (Tchol) |
197.3; 182.8; 178.5 | — |
| SECONDARY Serum Low Density Lipoprotein (LDL) |
93.5; 91.1; 96.3 | — |
| SECONDARY Serum High Density Lipoprotein (HDL) |
51.8; 46.1; 48 | — |
Eligibility Criteria
Inclusion Criteria:Age:
- 30 to 50 years,
- Fasting blood glucose ≥ 126 mg/dl
Exclusion Criteria
- Receiving vitamin D or calcium or omega-3 supplements within the last three months,
- On any medication which could potentially influence vitamin D metabolism (notably estrogens, and calcitonin) within the last three months,
- Any other concomitant disease such as renal, hepatic, and other endocrinological disorders, and malignancies, which could influence vitamin D metabolism.
- Receiving insulin or any change in the type and/or dose of the current hypoglycemic medications
Data sourced from ClinicalTrials.gov (NCT01229891). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.